- Home
- IFRX vs INDO Comparison
IFRX vs INDO Comparison
Compare IFRX & INDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- INDO
- Stock Information
- Founded
- IFRX 2007
- INDO 2018
- Country
- IFRX Germany
- INDO Indonesia
- Employees
- IFRX N/A
- INDO N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- INDO Oil & Gas Production
- Sector
- IFRX Health Care
- INDO Energy
- Exchange
- IFRX Nasdaq
- INDO Nasdaq
- Market Cap
- IFRX 53.5M
- INDO 45.6M
- IPO Year
- IFRX 2017
- INDO 2019
- Fundamental
- Price
- IFRX $1.43
- INDO $3.01
- Analyst Decision
- IFRX Strong Buy
- INDO
- Analyst Count
- IFRX 5
- INDO 0
- Target Price
- IFRX $7.40
- INDO N/A
- AVG Volume (30 Days)
- IFRX 492.5K
- INDO 447.0K
- Earning Date
- IFRX 11-07-2025
- INDO 10-24-2025
- Dividend Yield
- IFRX N/A
- INDO N/A
- EPS Growth
- IFRX N/A
- INDO N/A
- EPS
- IFRX N/A
- INDO N/A
- Revenue
- IFRX $191,224.00
- INDO $2,293,625.00
- Revenue This Year
- IFRX N/A
- INDO N/A
- Revenue Next Year
- IFRX $1,216.24
- INDO N/A
- P/E Ratio
- IFRX N/A
- INDO N/A
- Revenue Growth
- IFRX 54.36
- INDO N/A
- 52 Week Low
- IFRX $0.71
- INDO $2.10
- 52 Week High
- IFRX $2.82
- INDO $7.95
- Technical
- Relative Strength Index (RSI)
- IFRX 55.06
- INDO 52.86
- Support Level
- IFRX $1.29
- INDO $2.93
- Resistance Level
- IFRX $1.44
- INDO $3.06
- Average True Range (ATR)
- IFRX 0.14
- INDO 0.13
- MACD
- IFRX -0.00
- INDO 0.00
- Stochastic Oscillator
- IFRX 48.84
- INDO 36.79
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.